Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2.

MLA

Ong, Han Wee, et al. “Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2.” Molecules, vol. 29, no. 17, Sept. 2024, p. 4158. EBSCOhost, https://doi.org/10.3390/molecules29174158.

APA

Ong, H. W., Yang, X., Smith, J. L., Taft-Benz, S., Howell, S., Dickmander, R. J., Havener, T. M., Sanders, M. K., Brown, J. W., Couñago, R. M., Chang, E., Krämer, A., Moorman, N. J., Heise, M., Axtman, A. D., Drewry, D. H., & Willson, T. M. (2024). Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2. Molecules, 29(17), 4158. https://doi.org/10.3390/molecules29174158

Chicago

Ong, Han Wee, Xuan Yang, Jeffery L. Smith, Sharon Taft-Benz, Stefanie Howell, Rebekah J. Dickmander, Tammy M. Havener, et al. 2024. “Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2.” Molecules 29 (17): 4158. doi:10.3390/molecules29174158.